Breathe Well Live Well
|
US FDA approves Acton Pharma's Aerospan to treat asthma
pharmabiz.com The Centres for Disease Control (CDC) estimates that more than 24 million Americans have asthma and of these, more than half have an asthma attack each year. Annually, the disease is responsible for nearly two million emergency room visits and accounts … |
View full post on asthma – Google News
|
FDA approves asthma aerosol developed by Acton Pharmaceuticals
Boston.com Marlborough-based Acton Pharmaceuticals announced Thursday that the Food and Drug Administration has approved its supplemental new drug application for Aerospan Inhalation Aerosol, an asthma treatment for patients 6 years of age and older. Acton Says FDA Oks SNDA For AEROSPAN Inhalation Aerosol For Asthma |
View full post on asthma – Google News
|
Acton Says FDA Oks SNDA For AEROSPAN Inhalation Aerosol For Asthma
RTT News … has approved the sNDA (Supplemental New Drug Application) for AEROSPAN Inhalation Aerosol, a hydrofluoroalkane orally inhaled corticosteroid indicated for the maintenance treatment of asthma as a prophylactic therapy in adult and pediatric patients … |
View full post on asthma – Google News
|
Sanofi licenses hard-to-make asthma drug to Acton
FiercePharma Manufacturing Acton used the same approach in 2009–one year after it was formed–with Forest Labs ($FRX) to win a licensing deal for asthma treatment Aerospan. The NDA for this HFA-propelled aerosol inhaled corticosteroid was approved by the FDA in 2006. … Acton Pharmaceuticals, Inc. Announces License Agreement With |
View full post on asthma – Google News
|
Acton Pharma Says Trial Of Asthma Therapy Aerospan Shows No Growth Suppression
RTT News (RTTNews) – Privately-held Acton Pharmaceuticals Inc. Tuesday reported the publication of results of the Phase IIIb trial of Aerospan, a long-term asthma therapy, which said no suppression of growth and bone maturation was found in prepubescent … Acton Pharmaceuticals, Inc. Announces Publication of AEROSPAN(R) (Flunisolide … |
View full post on asthma – Google News
|
Acton Pharmaceuticals, Inc. Announces Publication of AEROSPAN(R) (Flunisolide …
MarketWatch (press release) AEROSPAN Inhalation Aerosol is an orally inhaled corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age and older. In this double-blind, placebo-controlled study, … |
View full post on asthma – Google News
|
Acton Pharmaceuticals, Inc. Submits NDA Supplement to FDA for AEROSPAN(R …
MarketWatch (press release) AEROSPAN is a hydrofluoroalkane (HFA) propelled inhaled corticosteroid for the treatment of asthma, which will compete in the $7 billion US inhaled steroid … |
View full post on asthma – Google News